Roivant director sells 17,750 shares after option exercise

Roivant Sciences Ltd. director Melissa B. Epperly exercised stock options and sold shares of the company on June 29, 2026.

Rhea-AI Filing Summary

Roivant Sciences Ltd. director Melissa B. Epperly exercised stock options and sold shares of the company on June 29, 2026. She exercised options to acquire 17,750 Common Shares at an exercise price of $4.46 per share, increasing her direct common share holdings before subsequent sales.

That same day, she executed open-market sales totaling 17,750 Common Shares in two transactions: 2,748 shares at a weighted average price of $34.71 and 15,002 shares at a weighted average price of $34.32. The footnotes state these were filled across multiple trades within price ranges from $33.65 to $34.80. After the transactions, Epperly directly held 16,474 Common Shares and 169,166 stock options to purchase additional shares, with the option grant exercised here fully vested and expiring on July 19, 2032.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Epperly Melissa B,

Role Director

Sold 17,750 shs ($610K)

Approx. gross sale proceeds $610K

Approx. exercise cost $79K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	17,750	$0.00	$0.00
Exercise	Common Shares	17,750	$4.46	$79K
Sale	Common Shares	15,002	$34.32	$515K
Sale	Common Shares	2,748	$34.71	$95K

Holdings After Transaction: Stock Option (Right to Buy) — 169,166 contracts (Direct); Common Shares — 16,474 shares (Direct)

Footnotes (3)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.65 to $34.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
3. F3. Reflects an award of stock options to purchase Common Shares that is fully vested.

Key Figures

Shares sold: 17,750 shares Weighted average sale price (lot 1): $34.71/share Weighted average sale price (lot 2): $34.32/share +5 more

8 metrics

Shares sold 17,750 shares Total Common Shares sold in open-market transactions on June 29, 2026

Weighted average sale price (lot 1) $34.71/share 2,748 Common Shares sold in one transaction

Weighted average sale price (lot 2) $34.32/share 15,002 Common Shares sold in another transaction

Options exercised 17,750 shares Stock options converted into Common Shares on June 29, 2026

Option exercise price $4.46/share Strike price for exercised stock options

Shares held after 16,474 shares Direct Common Share holdings following the reported transactions

Options held after 169,166 options Direct stock option holdings after the derivative transaction

Option expiration July 19, 2032 Expiration date of the stock option award exercised in part

Key Terms

open-market sale, Stock Option (Right to Buy), weighted average price, fully vested, +1 more

5 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested financial

"Reflects an award of stock options to purchase Common Shares that is fully vested."

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Roivant Sciences (ROIV) director Melissa Epperly report?

Melissa Epperly reported exercising options for 17,750 Roivant Sciences Common Shares and selling 17,750 shares in open-market transactions on June 29, 2026. These actions combined an option exercise with same-day share sales, a common liquidity pattern for insiders managing equity compensation.

How many Roivant Sciences (ROIV) shares did Melissa Epperly sell and at what prices?

She sold 17,750 Common Shares in total, including 2,748 shares at a weighted average of $34.71 and 15,002 shares at a weighted average of $34.32. Footnotes note multiple trades within ranges from $33.65 to $34.80 across these transactions.

What stock options did Melissa Epperly exercise in Roivant Sciences (ROIV)?

Epperly exercised fully vested stock options covering 17,750 Common Shares at an exercise price of $4.46 per share. The underlying option award is described as expiring on July 19, 2032, and is recorded as a direct holding of stock options following the transaction.

How many Roivant Sciences (ROIV) shares does Melissa Epperly hold after these transactions?

Following the June 29, 2026 trades, Epperly directly holds 16,474 Roivant Sciences Common Shares. The filing also shows 169,166 stock options as directly owned after the derivative transaction, indicating a remaining option position in addition to her common share holdings.

Were Melissa Epperly’s Roivant Sciences (ROIV) share sales made in a single trade or multiple trades?

The filing explains that each reported price is a weighted average for many individual trades. Shares were sold in multiple transactions within price ranges of $33.65–$34.64 and $34.65–$34.80, with full trade-by-trade details available upon request from the issuer or regulators.

What is the nature of Melissa Epperly’s Roivant Sciences (ROIV) ownership after the Form 4 transactions?

All reported holdings are classified as directly owned. After exercising options and selling shares, Epperly holds 16,474 Common Shares directly and 169,166 directly owned stock options, according to the post-transaction share and option balances listed in the Form 4 data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 06:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Epperly Melissa B,

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/29/2026		M		17,750	A	$4.46	34,224	D
Common Shares	06/29/2026		S		15,002	D	$34.32(1)	19,222	D
Common Shares	06/29/2026		S		2,748	D	$34.71(2)	16,474	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.46	06/29/2026		M			17,750	(3)	07/19/2032	Common Stock	17,750	$0	169,166	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.65 to $34.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

3. Reflects an award of stock options to purchase Common Shares that is fully vested.

Remarks:

	By: /s/ Jo Chen, as Attorney-in-Fact for Melissa B. Epperly	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)